DOCSLIB.ORG

Influence of Estrogenic Metabolic Pathway Genes Polymorphisms On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influence of Estrogenic Metabolic Pathway Genes Polymorphisms On pharmaceuticals Article Influence of Estrogenic Metabolic Pathway Genes Polymorphisms on Postmenopausal Breast Cancer Risk Micaela Almeida 1 , Mafalda Soares 1 , José Fonseca-Moutinho 1,2, Ana Cristina Ramalhinho 1,2 and Luiza Breitenfeld 1,* 1 Health Sciences Research Centre (CICS), Faculty of Health Sciences, University of Beira Interior (UBI), Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal; [email protected] (M.A.); [email protected] (M.S.); [email protected] (J.F.-M.); [email protected] (A.C.R.) 2 Academic Hospital of Cova da Beira (CHUCB), Quinta do Alvito, 6200-251 Covilhã, Portugal * Correspondence: [email protected]; Tel.: +351-2753-290-51 Abstract: Estrogen metabolism plays an important role in tumor initiation and development. Lifetime exposure to high estrogens levels and deregulation of enzymes involved in estrogen biosynthetic and metabolic pathway are considered risk factors for breast cancer. The present study aimed to evaluate the impact of mutations acquisition during the lifetime in low penetrance genes that codify enzymes responsible for estrogen detoxification. Genotype analysis of GSTM1 and GSTT1 null polymorphisms, CYP1B1 Val432Leu and MTHFR C677T polymorphisms was performed in 157 samples of women with hormone-dependent breast cancer and correlated with the age at diagnosis. The majority of patients with GSTT1 null genotype and with both GSTM1 and GSTT1 null genotypes were 50 years old or more at the diagnosis (p-value = 0.021 and 0.018, respectively). Older women with GSTM1 CYP1B1 p GSTT1 Citation: Almeida, M.; Soares, M.; null genotype were also carriers of the Val allele ( -value = 0.012). As well, null Fonseca-Moutinho, J.; Ramalhinho, and CYP1B1Val genotypes were correlated with diagnosis at later ages (p-value = 0.022). Similar A.C.; Breitenfeld, L. Influence of results were found associating MTHFR C677T and GSTT1 null polymorphism (p-value = 0.034). Our Estrogenic Metabolic Pathway Genes results suggest that estrogen metabolic pathway polymorphisms constitute a factor to be considered Polymorphisms on Postmenopausal simultaneously with models for breast cancer risk assessment. Breast Cancer Risk. Pharmaceuticals 2021, 14, 94. https://doi.org/ Keywords: breast cancer; GSTM1; GSTT1; CYP1B1; MTHFR 10.3390/ph14020094 Academic Editors: Raquel Lima and Marcelo Correia 1. Introduction Received: 21 January 2021 Breast cancer is the most common cancer in women, counting 2.1 million cases di- Accepted: 23 January 2021 Published: 27 January 2021 agnosed in 2018 [1]. Breast cancer risk has long been associated with reproductive and hormonal history, lifestyle and hereditary [2]. Mainly, these risk factors are related to exposure to high levels of endogenous or exogenous estrogens and to mutations inherited Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in or acquired during lifetime [3]. published maps and institutional affil- Estrogens metabolism plays an important role in tumor initiation and development, iations. estrogen being considered a carcinogen [4]. This fact is not only due to the exposure to high levels of estrogen and to estrogen receptor (ER) status, to which estrogen binds to exerts its actions, but also to the possible deregulation of the enzymes involved in the estrogen biosyn- thetic and metabolic pathway, such as Cytochrome P450, family 1, subfamily B, polypep- tide 1 (CYP1B1), glutathione S-transferases (GSTs) and 5,10-methylenetetrahydrofolate Copyright: © 2021 by the authors. reductase (MTHFR) [5–8]. Licensee MDPI, Basel, Switzerland. This article is an open access article CYP1B1, codified by the CYP1B1 gene, located on chromosome 2p21–p22, is a Phase I distributed under the terms and enzyme, responsible for generating 4-hydroxyestradiol (4-OH-E2), a catechol estrogen conditions of the Creative Commons metabolite (Figure1)[9]. Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Pharmaceuticals 2021, 14, 94. https://doi.org/10.3390/ph14020094 https://www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2021, 14, x FOR PEER REVIEW 2 of 9 Pharmaceuticals 2021, 14, 94 2 of 9 Figure 1. Schematic representation of the metabolic pathway of Oestradiol. CYP1B1 CYP1B1,, a Phase I enzyme, codified by the CYP1B1 gene,gene, leads leads to 4-OH-E2to 4-OH production.-E2 production. The Phase The IIPhase enzymes, II enzymes, COMT, codified COMT, by codified the COMT bygene, the andCOMT GSTM1/GSTT1, gene, and GSTM1/GSTT1,codified by GSTM1 codifiedand GSTT1 by GSTM1genes, and respectively, GSTT1 genes,inactivate respectively, the estrogen inactivate catechol, the semiquinoneestrogen cate andchol, quinone, semiquinone diminish- and quinone,ing DNA diminishing adducts formation. DNA adducts MTHFR, formation. an enzyme MTHFR, of the an folate enzyme metabolism, of the folate catalyzes metabolism,5,10-methylenetetrahydrofolate catalyzes 5,10-methylene- tetrahydrofolateto 5-methyltetrahydrofolate, to 5-methyltetrahydrofolate, which allows which the remethylation allows the remethylation of homocysteine of homocysteine to methionine, to methionine, a precursor a precursor of S- of S-adenosylmethionine (SAM). SAM is the methyl donor for COMT catalyzed reactions, allowing the inactivation of adenosylmethionine (SAM). SAM is the methyl donor for COMT catalyzed reactions, allowing the inactivation of cate- catechol estrogens. chol estrogens. AnAn important polymorphism in in CYP1B1 isis Val432Leu polymorphism, in in exon 3 (rs1056836;(rs1056836; location chromosome 2:38071060) [10]. [10]. Th Thisis polymorphism leads to an amino acidacid substitution ofof LeucineLeucine toto Valine,Valine, Val432 Val432 allele allele was was found found to to increase increase the the 4-hydroxilase 4-hydroxi- laseactivity activity ofCYP1B1 of CYP1B1 [11 [11].]. A A lack lack or or lowlow level of of Phase Phase II II detoxifying detoxifying enzymes, enzymes, such such as catecholas catechol-O-methyltransferase-O-methyltransferase (COMT) (COMT) and andGSTs GSTs,, might might lead leadto quinones to quinones accumulation, accumu- resultinglation, resulting in DNA inadducts DNA adductsformation formation and tumor and initiation tumor [3]. initiation Also, MTHFR [3]. Also, is involved MTHFR in is theinvolved conjugation in the and conjugation inactivation and of inactivation catechol estrogens of catechol by COMT. estrogens MTHFR by COMT. is the MTHFRkey en- zymeis the of key folate enzyme metabolism, of folate catalyzing metabolism, 5,10 catalyzing-methylenetetrahydrofolate 5,10-methylenetetrahydrofolate to 5-methyltetra- to hydrofolate,5-methyltetrahydrofolate, which allows the which remethylation allows the remethylationof homocysteine of to homocysteine methionine, toa precursor methion- ofine, S- aadenosylmethionine precursor of S-adenosylmethionine (SAM) [12]. In turn, (SAM) SAM [12 is]. the In turn,methyl SAM donor is the for methyl COMT donor cata- lyzedfor COMT reactions, catalyzed which reactions, allow inactivation which allow of inactivation catechol estrogens of catechol [12]. estrogens In this [regard,12]. In MTHFRthis regard, activity MTHFR alterations activity will alterations affect indirectly will affect the indirectly inactivation the of inactivation catechol estrogens of catechol by COMT.estrogens MTHFR by COMT. is codified MTHFR by the is codified MTHFR bygene, the locatedMTHFR ongene, chromosome located on1p36.3 chromosome [13]. One of1p36.3 the well [13].-studied One of the polymorphisms well-studied polymorphisms of MTHFR is the of MTHFR polymorphismis the polymorphism C677T (rs1801133, C677T location(rs1801133, chromosome location chromosome 1:11796321), 1:11796321), which leads which to a leads substitution to a substitution of alanine of alaninewith valine, with beingvaline, correlated being correlated with lower with activity lower activityof MTHFR of MTHFR[13,14]. Thus, [13,14 this]. Thus, polymorphism this polymorphism possibly affectspossibly COMT affects catalyzed COMT catalyzed reactions, reactions, compromi compromisingsing the catalyzation the catalyzation of 4-OH- ofE2 4-OH-E2 to 4-meth- to oxyestrogens4-methoxyestrogens (4-MeOE2) (4-MeOE2) [12]. [12]. TheThe GSTs, GSTs, a a superfamily superfamily of of Phase Phase II II enzymes, enzymes, are are responsible responsible for for metabolic metabolic detoxifi- detoxi- cationfication of of estrogen, estrogen, playing playing a akey key role role in in the the catalysis catalysis of glutathione (GSH) conjugation with catechol estrogen quinones, which are rapidly excreted by the cell [[3].3]. There are sevenseven classes classes of of cytosolic cytosolic GSTs: GSTs: alpha alpha (α), (α), mu mu (μ), (µ), kappa kappa (κ), (κ), pi pi (π), (π), theta theta (θ), (θ), omega (Ω) (W) andand zeta (ζ) (ζ)[ [15].15]. Among the polymorphisms studied in GSTs, Glutathione S-transferaseS-transferase ThetTheta1a1 ( (GSTT1GSTT1)) and and Glutathione Glutathione S- S-transferasetransferase Mu1 Mu1 (GSTM1 (GSTM1) null) null polymorphisms, polymorphisms, the ho- the mozygoushomozygous genotype genotype of which of which implies implies the total the total absence absence of the of enzyme, the enzyme, has previously has previously been relatedbeen related to breast to breast cancer cancer risk by risk our by research our research team team [16,17 [16]., GSTM117]. GSTM1 and andGSTT1 GSTT1 enzymes enzymes are are codified by the GSTM1 gene located on chromosome 1p13.3 and by the GSTT1 gene Pharmaceuticals 2021, 14, 94 3 of 9 located on chromosome 22q11.2, respectively [18–20].
Load more

Recommended publications
  • The 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer Whereas Resveratrol and N-Acetylcysteine Are the Preventers
    International Journal of Molecular Sciences Review The 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer whereas Resveratrol and N-acetylcysteine Are the Preventers Ercole Cavalieri 1 and Eleanor Rogan 2,* 1 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805, USA; [email protected] 2 Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, 984388 Nebraska Medical Center, Omaha, NE 68198-4388, USA * Correspondence: [email protected] Abstract: This article reviews evidence suggesting that a common mechanism of initiation leads to the development of many prevalent types of cancer. Endogenous estrogens, in the form of catechol estrogen-3,4-quinones, play a central role in this pathway of cancer initiation. The catechol estrogen- 3,4-quinones react with specific purine bases in DNA to form depurinating estrogen-DNA adducts that generate apurinic sites. The apurinic sites can then lead to cancer-causing mutations. The process of cancer initiation has been demonstrated using results from test tube reactions, cultured mammalian cells, and human subjects. Increased amounts of estrogen-DNA adducts are found not only in people with several different types of cancer but also in women at high risk for breast cancer, indicating that the formation of adducts is on the pathway to cancer initiation. Two compounds, resveratrol, and N-acetylcysteine, are particularly good at preventing the formation of estrogen-DNA Citation: Cavalieri, E.; Rogan, E. The adducts in humans and are, thus, potential cancer-prevention compounds. 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer whereas Keywords: cancer initiation; cancer prevention; estrogens; estrogen-DNA adducts; Resveratrol and N-acetylcysteine Are N-acetylcysteine; resveratrol the Preventers.
    [Show full text]
  • Pharmacokinetics of Ovarian Steroids in Sprague-Dawley Rats After Acute Exposure to 2,3,7,8-Tetrachlorodibenzo- P-Dioxin (TCDD)
    Vol. 3, No. 2 131 ORIGINAL PAPER Pharmacokinetics of ovarian steroids in Sprague-Dawley rats after acute exposure to 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD) Brian K. Petroff 1,2,3 and Kemmy M. Mizinga4 2Department of Molecular and Integrative Physiology,Physiology, 3Center for Reproductive Sciences, University of Kansas Medical Center, Kansas City, KS 66160. 4Department of Pharmacology,Pharmacology, University of Health Sciences, Kansas City,City, MO 64106 Received: 3 June 2003; accepted: 28 June 2003 SUMMARY 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces abnormalities in ste- roid-dependent processes such as mammary cell proliferation, gonadotropin release and maintenance of pregnancy. In the current study, the effects of TCDD on the pharmacokinetics of 17ß-estradiol and progesterone were examined. Adult Sprague-Dawley rats were ovariectomized and pretreated with TCDD (15 µg/kg p.o.) or vehicle. A single bolus of 17ß-estradiol (E2, 0.3 µmol/kg i.v.) or progesterone (P4, 6 µmol/kg i.v.) was administered 24 hours after TCDD and blood was collected serially from 0-72 hours post- injection. Intravenous E2 and P4 in DMSO vehicle had elimination half-lives of approximately 10 and 11 hours, respectively. TCDD had no signifi cant effect on the pharmacokinetic parameters of P4. The elimination constant 1Corresponding author: Center for Reproductive Sciences, Department of Molecular and Integra- tive Physiology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; e-mail: [email protected] Copyright © 2003 by the Society for Biology of Reproduction 132 TCDD and ovarian steroid pharmacokinetics and clearance of E2 were decreased by TCDD while the elimination half-life, volume of distribution and area under the time*concentration curve were not altered signifi cantly.
    [Show full text]
  • Urinary Concentrations of Estrogens and Estrogen Metabolites and Smoking in Caucasian Women
    Published OnlineFirst October 25, 2012; DOI: 10.1158/1055-9965.EPI-12-0909 Cancer Epidemiology, Research Article Biomarkers & Prevention Urinary Concentrations of Estrogens and Estrogen Metabolites and Smoking in Caucasian Women Fangyi Gu1, Neil E. Caporaso1, Catherine Schairer2, Renee T. Fortner5,6, Xia Xu4, Susan E. Hankinson5,6,7, A. Heather Eliassen5,6, and Regina G. Ziegler3 Abstract Background: Smoking has been hypothesized to decrease biosynthesis of parent estrogens (estradiol and estrone) and increase their metabolism by 2-hydroxylation. However, comprehensive studies of smoking and estrogen metabolism by 2-, 4-, or 16-hydroxylation are sparse. Methods: Fifteen urinary estrogens and estrogen metabolites (jointly called EM) were measured by liquid chromatography/tandem mass spectrometry (LC/MS-MS) in luteal phase urine samples collected during 1996 to 1999 from 603 premenopausal women in the Nurses’ Health Study II (NHSII; 35 current, 140 former, and 428 never smokers). We calculated geometric means and percentage differences of individual EM (pmol/mg creatinine), metabolic pathway groups, and pathway ratios, by smoking status and cigarettes per day (CPD). Results: Total EM and parent estrogens were nonsignificantly lower in current compared with never P ¼ smokers, with estradiol significant ( multivariate 0.02). We observed nonsignificantly lower 16-pathway EM (P ¼ 0.08) and higher 4-pathway EM (P ¼ 0.25) and similar 2-pathway EM in current versus never smokers. EM measures among former smokers were similar to never smokers. Increasing CPD was significantly associated with lower 16-pathway EM (P-trend ¼ 0.04) and higher 4-pathway EM (P-trend ¼ 0.05). Increasing CPD was significantly positively associated with the ratios of 2- and 4-pathway to parent estrogens (P-trend ¼ 0.01 and 0.002), 2- and 4-pathway to 16-pathway (P-trend ¼ 0.02 and 0.003), and catechols to methylated catechols (P-trend ¼ 0.02).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Estrogen Metabolism Tara Scott, MD
    7/15/2020 Estrogen Metabolism Tara Scott, MD. FACOG, FAAFM, ABOIM 1 Webinar Technical Issues & Clinical Questions •Please type any technical issue or clinical question into either the “Chat” or “Questions” boxes, making sure to send them to “Organizer” at any time during the webinar. •We will be compiling your clinical questions and answering as many as we can the final 15 minutes of the webinar. All rights reserved © 2020 Precision Analytical Inc. 2 1 7/15/2020 Need more resources? Ensure you have an account! • Contact Customer Service at 503.687.2050 or go to https://dutchtest.com/providers/ to open your account today! All rights reserved © 2020 Precision Analytical Inc. 3 WHO Am I? • Tara Scott, MD • Board certifications in: OB/GYN, Integrative Medicine, and Anti‐Aging, Functional and Regenerative Medicine • Lecture around the world teaching doctors a functional approach to women’s health • Medical Director of Integrative Medicine at Summa Health in Akron, OH Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP 4 2 7/15/2020 Objectives Review the basics of estrogen metabolism Define SNPs and how they affect metabolism Discuss which SNPs affect the risk of breast cancer Review a case and demonstrate the information the DUTCH test provides 5 Why is it so important to check estrogen metabolism? • Is it really possible to have a randomized placebo controlled trial with hormone therapy? • You need to consider: • Weight, age, oophorectomy status • Pharmacokinetics‐ what the body does to the drug • Pharmacodynamics‐ what the drug does to the body 6
    [Show full text]
  • Chapter 6: Estrogen Metabolism by Conjugation
    Chapter 6: Estrogen Metabolism by Conjugation Rebecca Raftogianis, Cyrus Creveling, Richard Weinshilboum, Judith Weisz trone and 17␤-estradiol, are both ligands for the ERs, although The involvement of estrogens in carcinogenic processes those receptors have higher affinity for 17␤-estradiol than for within estrogen-responsive tissues has been recognized for a estrone and it is 17␤-estradiol that is believed to be the predomi- number of years. Classically, mitogenicity associated with nant endogenous activator of ER-mediated cellular processes estrogen receptor-mediated cellular events was believed to (5). The most abundant circulating estrogen, however, is the be the mechanism by which estrogens contributed to carci- sulfate conjugate of estrone (8,9). The process by which estro- nogenesis. Recently, the possibility that estrogens might con- gens, synthesized and secreted predominantly by the ovaries, are tribute directly to mutagenesis resulting from DNA damage transported to and exert their biologic effects in steroid hormone has been investigated. That damage is apparently a result of target tissues is not completely understood. As will be discussed the formation of catechol estrogens that can be further oxi- in this chapter, estrogen conjugates, particularly estrone sulfates, dized to semiquinones and quinones. Those molecules rep- are believed to play an important role in that process (9–11). resent reactive oxygen species and electrophilic molecules Chemical carcinogenesis emerged as a scientific discipline that can form depurinating DNA adducts, thus having the approximately 50 years ago (12,13). One of the principles of that potential to result in permanent nucleotide mutation. Con- discipline is that compounds often require metabolic “activa- jugation of parent estrogens to sulfate and glucuronide moi- tion” to form genotoxic and carcinogenic metabolites (12,13).
    [Show full text]
  • Medical Hypothesis: Bifunctional Genetic-Hormonal Pathways
    Medical Hypothesis: Bifunctional screening practices do not explain geo- graphic variations in prevalence of the dis- Genetic-Hormonal Pathways ease (1-4). Inherited germ cell mutations occur in about 5% of all cases and in about to Breast Cancer 30% of cases under 40 years of age (3-6). The common tie linking most of the Devra Lee Davis,1 Nitin T. Telang," 2 Michael P. Osborne,2 established risk factors, aside from these and H. Leon Bradlow2 mutations, is greater cumulative exposure to bioavailable 17,-estradiol (E2) (4, 7-11). 1World Resources Institute, Washington, DC; 2Strang Cancer Research Bioavailable E2 is defined as a free hor- Laboratory, The Rockefeller University, New York, New York mone not bound to steroid hormone- binding globulin (SHBG) or weakly bound As inherited germ line mutations, such as loss of BRCA1 or AT, account for less than 5% of all to albumin (9-12). Women with elevated breast cancer, most cases involve acquired somatic perturbations. Cumulative lifetime exposure levels of bioavailable E2 have a 2- to 4-fold to bioavailable estradiol links most known risk factors (except radiation) for breast cancer. Based excess risk of breast cancer (10). Bio- on a series of recent experimental and epidemiologic findings, we hypothesize that the multistep available E2 can diffuse into cells and sub- process of breast carcinogenesis results from exposure to endogenous or exogenous hormones, sequently be taken into the nucleus where including phytoestrogens that directly or indirectly alter estrogen metabolism. Xenohormones are it can bind to the estrogen receptor (ER). defined as xenobiotic materials that modify hormonal production; they can work bifunctionally, The hormone also can be converted in the through genetic or hormonal paths, depending on the periods and extent of exposure.
    [Show full text]
  • Is It Necessary to Control the Level of Estrogen Receptor Α and ﾟ Activation in Postmenopausal Hormone Replacement Therapy In
    15-20 11/12/07 15:38 Page 15 MOLECULAR MEDICINE REPORTS 1: 15-20, 2008 15 Is it necessary to control the level of estrogen receptor α and ß activation in postmenopausal hormone replacement therapy in order to achieve the optimal outcome? (Review) BAO TING ZHU Department of Pharmacology, Toxicology and Therapeutics, School of Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA Received November 2, 2007; Accepted November 30, 2007 Abstract. Endogenous estrogens exert an array of biological Contents actions on women, many of which are mediated by the estrogen receptors (ERs) α and ß. Results from our recent 1. Introduction studies suggest that the human ERα and ERß systems are 2. Differences in the composition and quantity of endogenous differentially activated under different physiological condi- estrogens produced in pregnant and non-pregnant women tions. In non-pregnant young women, the ERα system is 3. Differences in the biological activity of pregnancy and preferentially activated over the ERß system, mainly by estrone non-pregnancy estrogens (E1) and its major oxidative metabolite, 2-hydroxy-E1. These 4. Biological activity of estrogens contained in Premarin two estrogens are among the quantitatively major estrogens 5. Which estrogens are ideal for postmenopausal hormone present in young women, and have approximately 4-fold replacement therapy? preferential activity for ERα over ERß. During pregnancy, 6. Concluding remarks however, there is a preponderance of activation of ERß over ERα conferred by various pregnancy estrogens such as estriol and other D-ring derivatives of 17ß-estradiol (E2). These 1. Introduction estrogens have an up to 18-fold preference for binding to ERß than for ERα, and some of them are produced in unusually Female hormone replacement therapy (HRT), also commonly large quantities.
    [Show full text]
  • Effect of Natural Compounds on Catechol Estrogen-Induced Carcinogenesis
    Biomedical Science Letters 2019, 25(1): 1 ~6 Review https://doi.org/10.15616/BSL.2019.25.1.1 eISSN : 2288-7415 Effect of Natural Compounds on Catechol Estrogen-Induced Carcinogenesis Nam-Ji Sung * and Sin-Aye Park †,** Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University, Asan 31538, Korea The hydroxylation of estradiol results in the formation of catechol estrogens such as 2-hydroxyestradiol (2-OHE 2) and 4-hydroxyestradiol (4-OHE 2). These catechol estrogens are further oxidized to quinone metabolites by peroxidases or cytochrome P450 (CYP450) enzymes. Catechol estrogens contribute to hormone-induced carcinogenesis by generating DNA adducts or reactive oxygen species (ROS). Interestingly, many of the natural products found in living organisms have been reported to show protective effects against carcinogenesis induced by catechol estrogens. Although some compounds have been reported to increase the activity of catechol estrogens via oxidation to quinone metabolites, many natural products decreased the activity of catechol estrogens by inhibiting DNA adduct formation, ROS production, or oxidative cell damage. Here we focus specifically on the chemopreventive effects of these natural compounds against carcinogenesis induced by catechol estrogens. Key Words: Catechol estrogen, 4-Hydroxyestradiol, Carcinogenesis, Natural compounds, Cancer prevention (CYP450), which may lead to the formation of DNA adducts INTRODUCTION or the generation of reactive oxygen species (ROS) (Cavalieri et al., 1997; Cavalieri et al., 2006). In addition, the increased Excessive exposure to estrogen increases the risk of breast level of quinone metabolites has been associated with cancer cancer and other types of hormone-related cancers. Cate- cell growth as well as DNA mutation or transformation in chol estrogens are active estrogen metabolites, formed by normal epithelial cells (Lareef et al., 2005; Cavalieri et al., aromatic hydroxylation of primary estrogens at either the 2006).
    [Show full text]
  • Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms
    COMBINED ESTROGEN−PROTESTOGEN MENOPAUSAL THERAPY 263 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion The distribution of progestogens is described in the monograph on Combined estro- gen–progestogen contraceptives. That of estrogens is described below. 4.1.1 Humans Little more has been discovered about the absorption and distribution of estrone, estradiol and estriol products and conjugated equine estrogens in humans since the previous evaluation (IARC, 1999). Greater progress has been made in the identification and characterization of the enzymes that are involved in estrogen metabolism and excre- tion. The various metabolites and the responsible enzymes, including genotypic varia- tions, are described below (see Figures 3 and 4). Sulfation and glucuronidation are the main metabolic reactions of estrogens in humans. (a) Metabolites (i) Estrogen sulfates Several members of the sulfotransferase (SULT) gene family can sulfate hydroxy- steroids, including estrogens. The importance of SULTs in estrogen conjugation is demons- trated by the observation that a major component of circulating estrogen is sulfated, i.e. estrone sulfate (reviewed by Pasqualini, 2004). In addition to the parent hormones, estrone and estradiol, SULTs can also conjugate their respective catechols and also methoxyestro- gens (Spink et al., 2000; Adjei & Weinshilboum, 2002). The resulting sulfated metabolites are more hydrophilic and can be excreted. In postmenopausal breast cancers, levels of estrone sulfate can reach 3.3 ± 1.9 pmol/g tissue, which is five to nine times higher than the corresponding plasma concentration (equating gram of tissue with millilitre of plasma) (Pasqualini et al., 1996). In contrast, levels of estrone sulfate in premenopausal breast tumours are two to four times lower than those in plasma.
    [Show full text]
  • Radiometric Analysis of Biological Oxidations in Man: Sex Differences in Estradiol Metabolism (Biological Activity/Chemical Oxidations) J
    Proc. Nati. Acad. Sci. USA Vol. 77, No. 8, pp. 4957-4960, August 1980 Medical Sciences Radiometric analysis of biological oxidations in man: Sex differences in estradiol metabolism (biological activity/chemical oxidations) J. FISHMAN, H. L. BRADLOW, J. SCHNEIDPER, K. E. ANDERSON, AND A. KAPPAS The Rockefeller University, 1230 York Avenue, New York, New York 10021 Communicated by Edward H. Ahrens, Jr., May 9,1980 ABSTRACT The oxidative metabolism of estradiol was the two classes of metabolites differ markedly in their biological studied in normal men and women by a radiometric procedure properties. The products of 16a-hydroxylation, estriol (5) and that provides information on the totality of the biotransforma- tions concerned. The release of 31 into body water from estra- 16a-hydroxyestrone (6), are now known to be potent utero- diol labeled with 3H in the 17a, 16a, and C-2 positions permits tropic agents under physiological conditions, whereas the al- measurement of the rate and extent of I7ft-ol oxidation and of ternative 2-hydroxylated compounds, 2-hydroxyestrone and the competing h droxylations at C-2 and 16a, which lead to 2-methoxyestrone, are devoid of such activity (7) but do exhibit products with dilferent biological properties. In both men and central nervous system actions (8, 9). women the oxidation is the most rapid transformation, followed by17P-ol2-hydroxylation and finally by 16a-hydroxylation. The oxidative pathways of estradiol metabolism delineated Hydroxylation at C-2 predominates by a factor of 2-4 over above create the opportunity for use of a radiometric method 16a-hydroxylation. In men a large fraction (37%) of the sub- that could provide a measure of the total extent of the principal strate is unmetabolized at any of the three sites and is not ex- metabolic transformations of estradiol in vivo in humans.
    [Show full text]
  • Nutritional Influences on Estrogen Metabolism
    MET451 1/01 APPLIED NUTRITIONAL SCIENCE REPORTS Copyright © 2001 by Advanced Nutrition Publications, Inc. Nutritional Influences on Estrogen Metabolism ABSTRACT: It is now well known that one of the most promi- estrogen metabolism can be accomplished through dietary and nent causes of breast cancer, as well as many other hormone lifestyle modifications such as increasing fiber and reducing fat, related health problems in both men and women, is excessive increasing phytoestrogen intake, losing weight, and increasing estrogen exposure from both endogenous and exogenous exercise. In addition, many nutrients effectively reduce estrogen sources. Improving estrogen metabolism can be of benefit in load by supporting preferred pathways of estrogen metabolism women with various conditions and family histories, including a and detoxification. These include isoflavones, indole-3-carbinol, family history of breast, uterine, or ovarian cancer, and condi- B vitamins, magnesium, limonene, calcium D-glucarate, and tions such as endometriosis, premenstrual syndrome, uterine antioxidants. The influences of these nutrients on estrogen fibroid tumors, fibrocystic or painful breasts, cervical dysplasia, metabolism may have profound significance for diseases and and systemic lupus erythematosis. Beneficial modulation of conditions in which estrogen plays a role in clinical expression. ESTROGEN PRODUCTION important point, because it means that any change in the concen- tration of SHBG will alter estrogen metabolism by inducing The term “estrogen” is used to collectively describe the female changes in the availability of estrogen to the target cell. hormones, the most potent of which is estradiol. The other important—but less powerful—estrogens are estrone and estri- ESTROGEN METABOLISM AND DETOXIFICATION ol. Estrogens affect the growth, differentiation, and function of diverse target tissues throughout the body—not just those Metabolism of estrogen within the body is a complex subject involved in the reproductive process.
    [Show full text]